ETF Building Blocks ChannelDrug Price Debate May Not Hinder Biotech ETFs After AllBy Tom LydonSeptember 16, 2021
ETF Building Blocks ChannelBiotech Stocks Have Colds, but They Can HealBy Tom LydonSeptember 13, 2021
ETF PrimeETF Prime: Tom Lydon Talks Pros & Cons of Market Cap WeightingBy Aaron NeuwirthSeptember 1, 2021
Innovative ETFs ChannelModerna Vaccine Is Granted Authorization in AustraliaBy Max ChenAugust 9, 2021
ETF Building Blocks ChannelWill the Biotech Space Consolidate in the Back Half of the Year?By Tom LydonJuly 14, 2021
ETF Building Blocks ChannelPost-Pandemic Healthcare Could Feature More Biotech M&ABy Tom LydonJune 10, 2021
ETF Building Blocks ChannelAs Biotech Consolidation Heats up, ‘SBIO’ Could Be a WinnerBy Tom LydonMay 24, 2021
Innovative ETFs ChannelGreater Regulatory Scrutiny Could Weigh on Biotech ETFsBy Max ChenMarch 24, 2021
Innovative ETFs ChannelIllumina Earnings, Forward Guidance Strengthen Biotech ETFsBy Max ChenFebruary 12, 2021
Innovative ETFs ChannelBiotechnology ETFs Soar on Biogen’s New Alzheimer’s DrugBy Max ChenJanuary 29, 2021
